Drug Trial Radar · NCT02715804
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Jul 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
492
Actual
Start
Mar 14, 2016
Primary completion
Nov 4, 2019
Study completion Nov 4, 2019
Sponsor
- Lead sponsor
- Halozyme TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 22, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with nab-paclitaxel plus gemcitabine (AG treatment), in participants with hyaluronan (HA)-high Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA).
Conditions
- Pancreatic Ductal Carcinoma
Interventions
Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)Other
PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
PlaceboDrug
Matching placebo for PEGPH20
nab-PaclitaxelDrug
Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
GemcitabineDrug
Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From randomization until death from any cause (maximum exposure: 150.1 weeks for PAG, and 83.9 weeks for AG)
Locations
217 sites in 22 countries. Site status is shown where the registry gives one.
University of South Alabama
Mobile, Alabama
Banner MD Anderson Cancer Center
Gilbert, Arizona
Highlands Oncology Group
Fayetteville, Arkansas
St. Jude Hospital Yorba DBA Linda St. Joseph Heritage Health
Fullerton, California
Scripps Clinical Research Services
La Jolla, California
Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California
David Geffen School of Medicine (DGSOM) at UCLA
Los Angeles, California
Chao Family Comprehensive Cancer Center
Orange, California
St. Joseph Hospital
Orange, California
Desert Hematology Oncology Medical Group, Inc.
Rancho Mirage, California
Cancer Care Associates Medical Group, Inc.
Redondo Beach, California
Pacific Hematology Oncology Associates
San Francisco, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Pacific Central Coast Health Centers: San Luis Obispo Oncology and Hematology Health Center
San Luis Obispo, California
St Joseph Heritage Healthcare
Santa Rosa, California
Innovative Clinical Research Institution
Whittier, California
Kaiser Permanente Franklin Medical Offices - Denver
Denver, Colorado
US Oncology - Rocky Mountain Cancer Centers - Midtown
Denver, Colorado
St. Mary's Medical Center
Grand Junction, Colorado
Yale Cancer Center
New Haven, Connecticut
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Memorial Healthcare System - Memorial Cancer Institute
Hollywood, Florida
21st Century Oncology
Jacksonville, Florida
MD Anderson Cancer Center Orlando
Orlando, Florida
Fort Wayne Medical Oncology/Hematology, INC.
Fort Wayne, Indiana
The University Of Kansas Cancer Center
Kansas City, Kansas
University of Louisville
Louisville, Kentucky
Ochsner Health Center
Baton Rouge, Louisiana
Ochsner Clinic CCOP
New Orleans, Louisiana
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
UMass Memorial Medical Center
Worcester, Massachusetts
University of Michigan Medical Center
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Virginia Piper Cancer Institute
Minneapolis, Minnesota
University of Minnesota Medical School
Minneapolis, Minnesota
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Renown Regional Medical Center
Reno, Nevada
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Saint Joseph's Ambulatory Clinic
Clifton, New Jersey
Showing 40 of 217 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.